Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
18
Enrollment
OTHER
Sponsor class
Conditions
Systemic Lupus Erythematosus (SLE)
Lupus Nephritis (LN)
Interventions
DRUG:
CD19 CAR-T cells
Sponsor
Beijing GoBroad Hospital